{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:02:29Z","timestamp":1793779349057,"version":"4.6.1"},"reference-count":109,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.diabet.2023.101419","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T05:38:23Z","timestamp":1673415503000},"page":"101419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit\/risk balance?"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9743-4371","authenticated-orcid":false,"given":"Andr\u00e9 J.","family":"Scheen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2023.101419_bib0001","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jacc.2019.06.053","article-title":"Cardiovascular aging and heart failure: JACC review topic of the week","volume":"74","author":"Triposkiadis","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2023.101419_bib0002","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCRESAHA.118.311371","article-title":"Heart failure in type 2 diabetes mellitus","volume":"124","author":"Kenny","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.diabet.2023.101419_bib0003","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s12933-021-01408-1","article-title":"Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management","volume":"20","author":"Ceriello","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabet.2023.101419_bib0004","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/14779072.2022.2098118","article-title":"Safety and efficacy considerations amongst the elderly population in the updated treatment of heart failure: a review","volume":"20","author":"Adams","year":"2022","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.diabet.2023.101419_bib0005","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41574-020-0392-2","article-title":"Sodium-glucose co-transporter type 2 inhibitors for the treatment of type 2 diabetes mellitus","volume":"16","author":"Scheen","year":"2020","journal-title":"Nature Rev Endocrinol"},{"key":"10.1016\/j.diabet.2023.101419_bib0006","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12933-021-01430-3","article-title":"SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabet.2023.101419_bib0007","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/ehf2.13785","article-title":"Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failure","volume":"9","author":"Usman","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.diabet.2023.101419_bib0008","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17425255.2022.2105693","article-title":"Counteracting heart failure with diabetes drugs: a review into the pharmacokinetic and pharmacodynamic properties","volume":"18","author":"Scheen","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.diabet.2023.101419_bib0009","doi-asserted-by":"crossref","DOI":"10.1007\/s10741-021-10182-x","article-title":"Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond","author":"Sciacqua","year":"2021","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.diabet.2023.101419_bib0010","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2023.101419_bib0011","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2023.101419_bib0012","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/14740338.2019.1602116","article-title":"An update on the safety of SGLT2 inhibitors","volume":"18","author":"Scheen","year":"2019","journal-title":"Expert Opin Drug Safety"},{"key":"10.1016\/j.diabet.2023.101419_bib0013","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0140-6736(05)17709-5","article-title":"Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2023.101419_bib0014","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jama.2013.285063","article-title":"How to use a subgroup analysis: users' guide to the medical literature","volume":"311","author":"Sun","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2023.101419_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0271668","article-title":"Interaction effect: are you doing the right thing?","volume":"17","author":"Garofalo","year":"2022","journal-title":"PLoS ONE"},{"key":"10.1016\/j.diabet.2023.101419_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101697","article-title":"Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: a systematic review and meta-analysis","volume":"54","author":"Diallo","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.diabet.2023.101419_bib0017","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2023.101419_bib0018","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2023.101419_bib0019","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2023.101419_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108114","article-title":"Efficacy of SGLT-2 inhibitors in older adults with diabetes: systematic review with meta-analysis of cardiovascular outcome trials","volume":"162","author":"Giugliano","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabet.2023.101419_bib0021","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/ageing\/afz096","article-title":"Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME(R) trial","volume":"48","author":"Monteiro","year":"2019","journal-title":"Age Ageing"},{"key":"10.1016\/j.diabet.2023.101419_bib0022","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","article-title":"Canagliflozin and heart failure in type 2 diabetes mellitus","volume":"138","author":"Radholm","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2023.101419_bib0023","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1530-891X(20)47079-X","article-title":"Outcomes with canagliflozin in patients by age subgroups: results from the Canvas Program","volume":"24","author":"Ovalle","year":"2018","journal-title":"Endocr Pract"},{"key":"10.1016\/j.diabet.2023.101419_bib0024","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2337\/dc19-1476","article-title":"Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE-TIMI 58 study","volume":"43","author":"Cahn","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2023.101419_bib0025","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1161\/CIRCULATIONAHA.118.033810","article-title":"Long-term benefit of empagliflozin on life expectancy in patients with type 2 diabetes mellitus and established cardiovascular disease","volume":"138","author":"Claggett","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2023.101419_bib0026","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2023.101419_bib0027","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1111\/dom.14386","article-title":"The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: analysis of the CREDENCE trial","volume":"23","author":"Arnott","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2023.101419_bib0028","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2023.101419_bib0029","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2023.101419_bib0030","article-title":"Empagliflozin in patients with chronic kidney disease","author":"Empa-Kidney Collaborative Group,","year":"2023388117","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2023.101419_bib0031","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2023.101419_bib0032","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2023.101419_bib0033","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2023.101419_bib0034","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2023.101419_bib0035","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2023.101419_bib0036","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/CIRCULATIONAHA.119.044133","article-title":"Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF","volume":"141","author":"Martinez","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2023.101419_bib0037","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/ejhf.2707","article-title":"Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR-Reduced","volume":"24","author":"Filippatos","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.diabet.2023.101419_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2022.04.040","article-title":"Empagliflozin improves outcomes in patients with heart failure and preserved ejection fraction irrespective of age","volume":"80","author":"Bohm","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2023.101419_bib0039","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.010080","article-title":"Efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to age: the DELIVER trial","volume":"15","author":"Peikert","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.diabet.2023.101419_bib0040","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2023.101419_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108737","article-title":"GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis","volume":"174","author":"Karagiannis","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabet.2023.101419_bib0042","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.42078","article-title":"Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in patients with type 2 diabetes and other risk factors for cardiovascular disease: a meta-analysis","volume":"5","author":"Bhattarai","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diabet.2023.101419_bib0043","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/1894155","article-title":"Eligibility of dapagliflozin and empagliflozin in a real-world heart failure population","volume":"2021","author":"Hakansson","year":"2021","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.diabet.2023.101419_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2022.101390","article-title":"Antidiabetic agents and risk of atrial fibrillation\/flutter: a comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists","author":"Scheen","year":"2022","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2023.101419_bib0045","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/dom.14261","article-title":"Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a nationwide population-based study","volume":"23","author":"Han","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2023.101419_bib0046","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/dom.14300","article-title":"Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a nationwide cohort study of older adults with diabetes mellitus","volume":"23","author":"Fralick","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2023.101419_bib0047","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12933-022-01586-6","article-title":"Contemporary use of SGLT2 inhibitors in heart failure patients with diabetes mellitus: a comparison of DPP4 inhibitors in a nationwide electric health database of the superaged society","volume":"21","author":"Nakai","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabet.2023.101419_bib0048","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.37606","article-title":"Comparative effectiveness of empagliflozin vs liraglutide or sitagliptin in older adults with diverse patient characteristics","volume":"5","author":"Htoo","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diabet.2023.101419_bib0049","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ahj.2022.09.008","article-title":"Comparative effectiveness of empagliflozin in reducing the burden of recurrent cardiovascular hospitalizations among older adults with diabetes in routine clinical care","volume":"254","author":"Desai","year":"2022","journal-title":"Am Heart J"},{"key":"10.1016\/j.diabet.2023.101419_bib0050","doi-asserted-by":"crossref","first-page":"826","DOI":"10.2337\/dc20-1464","article-title":"Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults","volume":"44","author":"Patorno","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2023.101419_bib0051","doi-asserted-by":"crossref","first-page":"e00183","DOI":"10.1002\/edm2.183","article-title":"Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: results from the EMPRISE East Asia study","volume":"4","author":"Seino","year":"2021","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.diabet.2023.101419_bib0052","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/dom.14593","article-title":"Effectiveness and safety of empagliflozin in routine care patients: results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study","volume":"24","author":"Patorno","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2023.101419_bib0053","doi-asserted-by":"crossref","first-page":"m3342","DOI":"10.1136\/bmj.m3342","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study","volume":"370","author":"Filion","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2023.101419_bib0054","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.46928","article-title":"Restricted mean survival time analysis to estimate SGLT2i-associated heterogeneous treatment effects on primary and secondary prevention of cardiorenal outcomes in patients with type 2 diabetes in Taiwan","volume":"5","author":"Peng","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diabet.2023.101419_bib0055","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.diabet.2023.101419_bib0056","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ijcard.2022.09.059","article-title":"Impact of SGLT2 inhibitors on old age patients with heart failure and chronic kidney disease","volume":"370","author":"Amioka","year":"2023","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.diabet.2023.101419_bib0057","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/jgs.17585","article-title":"Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure","volume":"70","author":"Perez-Belmonte","year":"2022","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.diabet.2023.101419_bib0058","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S2213-8587(17)30258-9","article-title":"Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis","volume":"5","author":"Birkeland","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2023.101419_bib0059","doi-asserted-by":"crossref","first-page":"l4772","DOI":"10.1136\/bmj.l4772","article-title":"Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study","volume":"366","author":"Pasternak","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2023.101419_bib0060","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12933-017-0575-x","article-title":"Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis","volume":"16","author":"Gautam","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabet.2023.101419_bib0061","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/dom.13477","article-title":"Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes","volume":"21","author":"Dawwas","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2023.101419_bib0062","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1472-6823-14-37","article-title":"Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies","volume":"14","author":"Sinclair","year":"2014","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.diabet.2023.101419_bib0063","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/jgs.14028","article-title":"Efficacy and safety of canagliflozin in individuals aged 75 and older with type 2 diabetes mellitus: a pooled analysis","volume":"64","author":"Sinclair","year":"2016","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.diabet.2023.101419_bib0064","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s40266-016-0382-1","article-title":"Long-term safety of dapagliflozin in older patients with type 2 diabetes mellitus: a pooled analysis of phase IIb\/III studies","volume":"33","author":"Fioretto","year":"2016","journal-title":"Drugs Aging"},{"key":"10.1016\/j.diabet.2023.101419_bib0065","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s12325-017-0573-0","article-title":"Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials","volume":"34","author":"Kohler","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.diabet.2023.101419_bib0066","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1007\/s12325-020-01329-7","article-title":"Pooled safety and tolerability analysis of empagliflozin in patients with type 2 diabetes mellitus","volume":"37","author":"Kinduryte Schorling","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.diabet.2023.101419_bib0067","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1111\/dom.14150","article-title":"Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: a pooled analysis of phase III studies","volume":"22","author":"Pratley","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2023.101419_bib0068","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s00125-019-4839-8","article-title":"Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program","volume":"62","author":"Matthews","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2023.101419_bib0069","doi-asserted-by":"crossref","first-page":"m2812","DOI":"10.1136\/bmj.m2812","article-title":"Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study","volume":"370","author":"Fralick","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2023.101419_bib0070","doi-asserted-by":"crossref","first-page":"k4365","DOI":"10.1136\/bmj.k4365","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2023.101419_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2022.101325","article-title":"Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors ?","volume":"48","author":"Scheen","year":"2022","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2023.101419_bib0072","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1053\/j.ajkd.2021.09.015","article-title":"SGLT2 inhibitors and the risk of acute kidney injury in older adults with type 2 diabetes","volume":"79","author":"Zhuo","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabet.2023.101419_bib0073","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2021.101315","article-title":"Acute renal injury events in diabetic patients treated with SGLT2 inhibitors: a comprehensive review with a special reference to RAAS blockers","volume":"48","author":"Scheen","year":"2022","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2023.101419_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106396","article-title":"SGLT2-inhibitors are effective and safe in the elderly: the SOLD study","volume":"183","author":"Lunati","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.diabet.2023.101419_bib0075","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/jch.14131","article-title":"Safety and efficacy of empagliflozin in elderly Japanese patients with type 2 diabetes mellitus: a post hoc analysis of data from the SACRA study","volume":"23","author":"Okada","year":"2021","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.diabet.2023.101419_bib0076","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s12325-021-01984-4","article-title":"Real-world safety and effectiveness of canagliflozin treatment for type 2 diabetes mellitus in Japan: SAPPHIRE, a long-term, large-scale post-marketing surveillance","volume":"39","author":"Inagaki","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.diabet.2023.101419_bib0077","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.2337\/dc22-S013","article-title":"13. Older adults: standards of medical care in diabetes-2022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2023.101419_bib0078","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.hfc.2022.03.002","article-title":"SGLT2 inhibitors and safety in older patients","volume":"18","author":"Pollack","year":"2022","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.diabet.2023.101419_bib0079","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1080\/14656566.2021.1912735","article-title":"Careful use to minimize adverse events of oral antidiabetic medications in the elderly","volume":"22","author":"Scheen","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.diabet.2023.101419_bib0080","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ijcard.2022.10.155","article-title":"Do SGLT2 inhibitors protect elderly patients from HF rehospitalization and CKD progression? More opportunities than concerns","volume":"370","author":"Galassi","year":"2023","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.diabet.2023.101419_bib0081","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/dom.14055","article-title":"Cardiovascular protection with sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: does it apply to all patients?","volume":"22","author":"Giorgino","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2023.101419_bib0082","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11892-016-0789-4","article-title":"SGLT2 inhibitors: benefit\/risk balance","volume":"16","author":"Scheen","year":"2016","journal-title":"Cur Diabetes Rep"},{"key":"10.1016\/j.diabet.2023.101419_bib0083","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2021.101275","article-title":"Efficacy \/safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes","volume":"47","author":"Scheen","year":"2021","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2023.101419_bib0084","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/CIRCRESAHA.117.311588","article-title":"Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors","volume":"122","author":"Scheen","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.diabet.2023.101419_bib0085","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jacc.2022.04.037","article-title":"Empagliflozin and elderly patients with preserved ejection fraction heart failure: is age just a number?","volume":"80","author":"Sauer","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2023.101419_bib0086","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s13300-021-01035-9","article-title":"Diabetes and frailty: an expert consensus statement on the management of older adults with type 2 diabetes","volume":"12","author":"Strain","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabet.2023.101419_bib0087","doi-asserted-by":"crossref","first-page":"afac201","DOI":"10.1093\/ageing\/afac201","article-title":"The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus","volume":"51","author":"Evans","year":"2022","journal-title":"Age Ageing"},{"key":"10.1016\/j.diabet.2023.101419_bib0088","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/M21-4776","article-title":"Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction: a post hoc analysis of the DAPA-HF trial","volume":"175","author":"Butt","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabet.2023.101419_bib0089","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1161\/CIRCULATIONAHA.122.061754","article-title":"Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial","volume":"146","author":"Butt","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2023.101419_bib0090","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11892-021-01417-0","article-title":"Interpreting absolute and relative risk reduction in the context of recent cardiovascular outcome trials in patients with type 2 diabetes","volume":"21","author":"Berg","year":"2021","journal-title":"Curr Diabetes Rep"},{"key":"10.1016\/j.diabet.2023.101419_bib0091","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"Kidney Disease: improving Global Outcomes Diabetes Work G. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabet.2023.101419_bib0092","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2023.101419_bib0093","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/17446651.2022.2014322","article-title":"Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease","volume":"17","author":"Scheen","year":"2022","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.diabet.2023.101419_bib0094","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.diabet.2017.04.004","article-title":"Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes","volume":"43","author":"Bonnet","year":"2017","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2023.101419_bib0095","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3390\/ph13110379","article-title":"Perspective of SGLT2 inhibition in treatment of conditions connected to neuronal loss: focus on Alzheimer's disease and ischemia-related brain injury","volume":"13","author":"Wicinski","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.diabet.2023.101419_bib0096","doi-asserted-by":"crossref","DOI":"10.1177\/20406223221086996","article-title":"Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review","volume":"13","author":"Tharmaraja","year":"2022","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.diabet.2023.101419_bib0097","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2019.100944","article-title":"Diabetes mellitus and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 144 prospective studies","volume":"55","author":"Xue","year":"2019","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.diabet.2023.101419_bib0098","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/MED.0000000000000783","article-title":"Type 2 diabetes mellitus and cognitive function: understanding the connections","volume":"30","author":"Dao","year":"2023","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.diabet.2023.101419_bib0099","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S2213-8587(20)30118-2","article-title":"Type 2 diabetes and cognitive dysfunction-towards effective management of both comorbidities","volume":"8","author":"Srikanth","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2023.101419_bib0100","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.3390\/molecules26237213","article-title":"Neuroprotective effect of SGLT2 inhibitors","volume":"26","author":"Pawlos","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.diabet.2023.101419_bib0101","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.823569","article-title":"The intersection of SGLT2 inhibitors, cognitive impairment, and CKD","volume":"13","author":"Noel","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.diabet.2023.101419_bib0102","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106062","article-title":"Cognitive impairment and type 2 diabetes mellitus: focus of SGLT2 inhibitors treatment","volume":"176","author":"Rizzo","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.diabet.2023.101419_bib0103","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3233\/JAD-215678","article-title":"Association between use of sodium-glucose co-transporter-2 (SGLT2) inhibitors and cognitive function in a longitudinal study of patients with type 2 diabetes","volume":"87","author":"Low","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.diabet.2023.101419_bib0104","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.747620","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors vs. dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset dementia: a propensity score-matched population-based study with competing risk analysis","volume":"8","author":"Mui","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.diabet.2023.101419_bib0105","article-title":"Association of sodium-glucose cotransporter-2 inhibitors with time to dementia: a population-based cohort study","author":"Wu","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2023.101419_bib0106","doi-asserted-by":"crossref","DOI":"10.1177\/14791641221098168","article-title":"The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: a nationwide population-based longitudinal cohort study","volume":"19","author":"Siao","year":"2022","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.diabet.2023.101419_bib0107","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2337\/dc21-2434","article-title":"Empagliflozin improves cognitive impairment in frail older adults with type 2 diabetes and heart failure with preserved ejection fraction","volume":"45","author":"Mone","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2023.101419_bib0108","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-045844","volume":"11","author":"Yabe","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.diabet.2023.101419_bib0109","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/ageing\/afab157","article-title":"Individualisation of glycaemic management in older people with type 2 diabetes: a systematic review of clinical practice guidelines recommendations","volume":"50","author":"Christiaens","year":"2021","journal-title":"Age Ageing"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363623000010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363623000010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:59:21Z","timestamp":1761130761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363623000010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":109,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1262363623000010"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2023.101419","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit\/risk balance?","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2023.101419","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101419"}}